According to a recent LinkedIn post from Circulate, CEO Dr. Brad Younggren is speaking at the Longevity SD Summit 2026 in San Diego on the clinical use of Therapeutic Plasma Exchange (TPE) in the context of healthy aging. The post indicates his talk emphasizes moving TPE from a longstanding hospital-based therapy into the outpatient longevity market, positioned as grounded in decades of medical use and emerging longevity research.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights TPE as potentially impactful across conditions tied to inflammation, immune dysfunction, and age-related decline, suggesting that evidence for broader longevity-focused applications is building. For investors, this visibility at a specialized longevity conference may signal Circulate’s intent to position itself as an early mover in translating established therapies into new care models, which could support future demand, partnership opportunities, and differentiation within the growing longevity and healthspan sector.